Cargando…
Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach
Background and Aim. Cholangiocarcinoma (CCA) is the most frequent biliary malignancy, which poses high mortality rate due to lack of early detection. Hence, most CCA cases are present at the advanced to late stages with local or distant metastasis at the time of diagnosis. Currently available tumor...
Autores principales: | Janvilisri, Tavan, Leelawat, Kawin, Roytrakul, Sittiruk, Paemanee, Atchara, Tohtong, Rutaiwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427802/ https://www.ncbi.nlm.nih.gov/pubmed/26060332 http://dx.doi.org/10.1155/2015/105358 |
Ejemplares similares
-
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
por: Leelawat, Kawin, et al.
Publicado: (2011) -
CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2
por: LEELAWAT, KAWIN, et al.
Publicado: (2013) -
Role of mTOR inhibitor in cholangiocarcinoma cell progression
por: MOOLTHIYA, PENPAK, et al.
Publicado: (2014) -
Downregulation of ABCA1 and ABCG1 transporters by simvastatin in cholangiocarcinoma cells
por: Seeree, Pattaya, et al.
Publicado: (2019) -
Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling
por: Likhitrattanapisal, Somsak, et al.
Publicado: (2020)